SCHEMBL6674871

SCHEMBL6674871

COc1ccccc1N1CCN(C(=Nc2cc3ccccc3nc2OC)NO)CC1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTR1A P08908 4/20 0.45
PHGDH O43175 1/20 0.44
DRD2 P14416 2/20 0.43
DRD3 P35462 2/20 0.43
ADRA1A P35348 1/20 0.43
KMT2A Q03164 1/20 0.42
HTR7 P34969 1/20 0.42
AKR1C3 P42330 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6672526 0.87 ALDH1A1 (0.47) NPC1RAB9AALDH1A1CYP1A2CYP3A4
SCHEMBL6674569 0.84 GAA (0.43) NPC1RAB9AALDH1A1CYP1A2CYP3A4
SCHEMBL6672232 0.84 GAA (0.38) ALDH1A1CYP3A4HTR1APHGDHKMT2A
SCHEMBL6673628 0.84 PKM (0.46) RAB9AALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL6673923 0.83 GAA (0.37) ALDH1A1HTR1APHGDHKMT2A
SCHEMBL6675674 0.83 MAPT (0.46) RAB9AALDH1A1PHGDHADRA1AKMT2A
SCHEMBL6686206 0.81 NPC1 (0.46) NPC1RAB9AALDH1A1HTR1AKMT2A
SCHEMBL6674877 0.80 RAB9A (0.50) NPC1RAB9AALDH1A1CYP1A2CYP3A4
SCHEMBL6650534 0.76 PHGDH (0.59) NPC1RAB9AALDH1A1CYP1A2CYP3A4
SCHEMBL6966945 0.76 MAPT (0.57) NPC1RAB9AALDH1A1HTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1424072-A1 N'-(pyridin-3-yl)-(4-phenylpiperazin-1-yl)-carboxyimidamide and -iminothiolate derivatives for the treatment of tumors Samjin Pharmaceutical Co., Ltd. (KR) 2004-06-02 EP disclosed
US-6683184-B2 ANTITUMOR AGENTS SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2004-01-27 US disclosed
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS NPC1 287/4885RAB9A 2925/4885ALDH1A1 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.